Menu
Recruiting NCT03527992

Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia

No phase Interventional Pneumonia Pneumonia, Ventilator-Associated Length of Stay

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: O2 automated, O2 standard.
Who it may be relevant to
Registry conditions: Pneumonia, Pneumonia, Ventilator-Associated, Length of Stay. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Hypoxemic pneumonia is a major cause of hospitalization in Pulmonology. The patient's dependency on oxygen prevents early discharge from the hospital. An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. This system has proven to be particularly effective with chronic obstructive pulmonary disease (COPD) patients, by decreasing the time spent in hypoxia and hyperoxia, and by accelerating the weaning of oxygen. Our hypothesis is that automated oxygen therapy leads to a diminution on the length of hospital stay.

Detailed description

Prolonged hospitalization has many consequences, including loss of autonomy and nosocomial infection. Moreover, these complications themselves lead to an extension of the length of stay. This has an impact on the cost of care: several studies have shown that hospitalization is the most costly factor in the management of pneumonia, and that even a small amount of hospital stay, led to significant financial savings. Automated oxygen therapy is a device that automatically adjusts with the saturation the amount of oxygen administered. Investigator hypothesis is that automated oxygen therapy could shorten the length of stay of patients hospitalized for hypoxemic pneumonia. One group of patients will receive the automated oxygen therapy and the other group will receive the standard Oxygen therapy. The investigator will compare in each group the average length of stay, the duration of oxygen therapy, the time spent outside of the target saturation, the cost on the medical-economic level and the patient's experience.

Interventions

  • Device O2 automated
    In the "O2 automated" group, patients benefit from oxygen therapy via the "FreeO2" device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates.
  • Device O2 standard
    In the "O2 standard" group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care

Primary outcome measures

  • Length in days of hospital stay [Time frame: 1 month]
Secondary outcome measures (5)
  • Duration of oxygen therapy [Time frame: 1 month]
  • Time spent outside of the target saturation [Time frame: 1 month]
  • the cost on the medical-economic level [Time frame: 1 month]
  • rate of medical complication [Time frame: 1 month]
  • quality questionnaire of patient's life during hospitalization [Time frame: 1 month]

Eligibility criteria

Inclusion criteria

  • Adult
  • Patient living at home or in an institution
  • Patient hospitalized for less than 48 hours
  • Pneumonia defined (according to the 2006 French-speaking infectious pneumology society (SPILF) criteria) by:
  • respiratory functional symptoms (cough, sputum, dyspnea, chest pain) and
  • Hyperthermia >38,5°C or hypothermia <36°C and
  • Radiological Signs of Pneumonia
  • Hypoxia : SpO2 < 94% in ambient air and/or PaO2< 60 mmHg in ambient air

Exclusion criteria

  • Pneumonia acquired at the hospital.
  • Patient hospitalized in another department more than 48 hours before admission
  • Chronic respiratory failure
  • Active neoplasia
  • Patients undergoing oxygen therapy and / or long-term NIV
  • Associated cardiac decompensation (clinical signs and / or NTproBNP> 1800ng / mL) (3
  • Initial Need for high flow oxygen therapy or ventilatory support (NIV, VI)
  • Difficulties expected from home support.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

France · 1 center
  • CHU Larrey — Toulouse

Identifiers

NCT: NCT03527992 · RC31/17/0404 · 2017-A03642-51

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗